Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc filed a shelf registration under Form S-3 to permit the periodic offering of debt securities by Medtronic Global Holdings S.C.A. and Medtronic, Inc., to be offered "from time to time after this registration statement becomes effective."
The prospectus states debt issued by each issuer will be fully and unconditionally guaranteed on a joint and several basis by the other group members named, and that specific terms, amounts and distribution methods will be provided in prospectus supplements.
Medtronic plc filed an initial ownership report for MiniMed Group, Inc., stating indirect beneficial ownership of 252,813,348 shares of MiniMed common stock. This Form 3 does not report new share purchases or sales, but formally records Medtronic as a more than 10% owner.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares. On February 19, 2026, he exercised multiple stock options (rights to buy), converting them into ordinary shares at exercise prices reflected as $0.0000 per option in the derivative rows.
On the same date, he conducted several open-market sales of ordinary shares coded as "S," totaling 52,524 shares sold according to the transaction summary. Sale prices for these transactions include individual entries around $97.66 to $97.86, with a footnote stating a weighted average sale price and an actual range from $97.60 to $97.775.
Following these exercises and sales, his directly held ordinary share balance shown in the final row is 32,768 shares. A footnote also notes that this total includes 239 shares acquired through dividend reinvestment since his prior report.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a bona fide gift of 340 Ordinary Shares of Medtronic on February 20, 2026. The gift was reported at a price of $0.00 per share, indicating no consideration was received for the transfer.
Following this charitable or personal gift transaction, Blomquist’s directly held stake stands at 11,966 Ordinary Shares of Medtronic. The filing reflects a disposition of shares through gifting rather than an open-market sale or purchase.
Medtronic plc reported fiscal Q3 2026 net sales of $9.0 billion, up from $8.3 billion a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Operating profit declined to $1.5 billion, and net income attributable to Medtronic fell to $1.1 billion, with diluted EPS at $0.89 versus $1.01.
For the first nine months, revenue reached $26.6 billion, up from $24.6 billion, while net income was roughly flat at $3.6 billion and diluted EPS was $2.76. Strong operating cash flow of $4.8 billion funded $2.7 billion in dividends and $0.6 billion of share repurchases, even as long‑term debt rose to $27.9 billion.
The company is preparing to separate its Diabetes business into MiniMed, an independent public company, and has launched a restructuring program expected to cost $300–$500 million through fiscal 2029. Medtronic also recorded higher restructuring and certain litigation charges and continued using derivative and funding arrangements to manage currency, interest rate, and development risks.
Filer reports proposed sale of Common stock via Form 144. The filing lists proposed dispositions of Common shares tied to restricted stock vesting and option exercises with transaction dates including 12/06/2025 and filing date 02/19/2026. Examples shown include Fidelity Brokerage Services LLC 52,524 and an individual grant-related lot of 30,568 shares.
Medtronic plc reported strong third quarter fiscal 2026 results, with revenue of $9.017 billion, up 8.7% as reported and 6.0% on an organic basis, slightly ahead of guidance.
GAAP diluted EPS was $0.89, while non-GAAP diluted EPS was $1.36, three cents above the guidance mid-point. Cardiovascular revenue rose 13.8% to $3.457 billion and Diabetes revenue grew 14.8% to $796 million, with Cardiac Ablation Solutions up 80% on strength in pulsed field ablation.
The company reiterated its FY26 organic revenue growth outlook of about 5.5% and non-GAAP EPS guidance of $5.62 to $5.66, including a possible $185 million tariff impact. Medtronic also highlighted multiple regulatory milestones, including U.S. FDA clearances for its Hugo robotic-assisted surgery system and Stealth AXiS Surgical System, CE Mark for Sphere-360, and two M&A deals in coronary, renal denervation, and structural heart.
Medtronic plc’s Chief Accounting Officer, Denise L. Blomquist, reported an automatic share withholding related to equity compensation. On 01/29/2026, 148 Ordinary Shares were withheld at $101 per share to cover taxes upon the vesting of previously reported restricted stock units.
After this tax withholding, Blomquist beneficially owns 12,306 Medtronic Ordinary Shares directly, which includes 97 shares acquired through dividend reinvestment since her last report.
Medtronic plc reported a routine insider transaction by one of its executives. The officer, listed as EVP & President Neuroscience, had 439 ordinary shares withheld on 12/15/2025 to pay taxes due when previously granted restricted stock units vested, at a price of $99.87 per share.
After this tax-withholding transaction, the reporting person directly owns 54,749 Medtronic ordinary shares. This total includes 251 shares that were acquired through dividend reinvestment since the prior report.